SCCA at the San Antonio Breast Cancer Symposium

More than a dozen Seattle Cancer Care Alliance (SCCA) and Fred Hutch physicians and researchers who are leaders in breast oncology will be at the San Antonio Breast Cancer Symposium December 4-8. The symposium provides the latest information on the experimental biology, etiology, prevention, diagnosis and therapy of breast cancer and premalignant breast disease.

San Antonio Breast Cancer Symposium

More than a dozen Seattle Cancer Care Alliance (SCCA) and Fred Hutch physicians and researchers who are leaders in breast oncology will be at the San Antonio Breast Cancer Symposium December 4-8. The symposium provides the latest information on the experimental biology, etiology, prevention, diagnosis and therapy of breast cancer and premalignant breast disease.

SCCA physicians are experts in the full spectrum of breast cancer treatments. We have a state-of-the-art Breast Cancer Specialty Center and nearly 40 currently enrolling breast cancer clinical trials.

Our breast oncology experts will be presenting their research in both poster sessions and spotlight sessions throughout the five-day symposium.

Tuesday, December 4

ES5‐3 Late recurrence in ER‐positive breast cancer
Educational Session 5 (3:45 ‐ 5:15 pm) Room: Hemisfair Ballroom ‐ 3rd Level
Julie R. Gralow, MD

Wednesday, December 5

A phase 2 study of low dose metronomic eribulin in metastatic breast cancer
Poster Session 1: Treatment: Advanced chemotherapy (5 – 7 pm) Room: Hall 1
VK Gadi, MD, PhDJennifer Specht, MDHannah M. Linden, MD

Statin use, site of recurrence, and survival among post‐menopausal women taking bisphosphonates as adjuvant therapy for breast cancer (SWOG S0307)
Poster Session 1: Treatment: Adjuvant therapy — other (5 – 7 pm) Room: Hall 1
Julie R. Gralow, MD

Thursday, December 6

Screening, diagnosis & residual disease detection
Spotlight Session: Breast Cancer Screening and Imaging (7‐9 amRoom: Stars at Night Ballroom 3&4
Janie M. Lee, MD, MSc

18F‐fluoroestradiol (FES) and 18F‐fluorodeoxyglucose (FDG) PET imaging in staging extent of disease in metastatic lobular breast cancer
Spotlight Session: Imaging (7 – 9 am) Room: Stars at Night Ballroom 3 & 4
Jennifer Specht, MDHannah M. Linden, MD

Use of breast cancer index to analyze tumor proliferation and endocrine responsiveness in genomic intermediate risk patients
Poster Session 2: Prognostic and Predictive Factors: other (7:30 – 9 am) Room: Hall 1
VK Gadi, MD, PhD

A phase I study of adoptive immunotherapy for ROR1+ advanced triple negative breast cancer (TNBC) with defined subsets of autologous T cells expressing a ROR1‐specific chimeric antigen receptor (ROR1‐CAR)
Poster Session 2: Treatment: Immunotherapy (clinical) (7:30 – 9 am) Room: Hall 1
Jennifer Specht, MD

CD8 T cells induced by novel alphaviral vector predict improved progression free survival in advanced HER2+ breast cancer patients
Poster Session 2: Treatment: Immunotherapy (clinical) (7:30 ‐ 9 am) Room: Hall 1
William R. Gwin, MD

Genetic testing and bilateral mastectomy for women with breast cancer: Does testing matter more than the test result?
Poster Session 2: Treatment: Surgery (7:30 – 9 am) Room: Hall 1
Benjamin O. Anderson, MDSarah H. Javid, MD

Lifestyle intervention study (LISA) in early breast cancer (BC): An RCT of the effects of a telephone‐based weight loss intervention (with educational materials) vs educational materials alone on disease‐free survival (DFS)
Spotlight Session: QOL & Survivorship (5 ‐7 pm) Room: Stars at Night Ballroom 3 & 4
Julie R. Gralow, MD

A novel six‐parameter assay for comprehensive phenotyping of circulating tumor cells
Poster Session 3: Detection/Diagnosis: Circulating tumor cells (5-7 pm) Room: Hall 1
VK Gadi, MD, PhD

Durability of clinical benefit with niraparib + pembrolizumab in patients with advanced triple‐negative breast cancer beyond BRCA: (TOPACIO/Keynote‐162)
Spotlight Session: Immunotherapy (5 – 7 pm) Room: Stars at Night Ballroom 1 & 2
Shaveta Vinayak, MD, MS

Spatial mapping of the immune microenvironment in primary triple‐negative breast cancer (TNBC) and association with neoadjuvant therapy response
Spotlight Session: Immunotherapy (5 – 7 pm) Room: Stars at Night Ballroom 1 & 2
Shaveta Vinayak, MD, MS

A phase 2 study of intratumoral tavokinogene telseplasmid (tavo) plus electroporation with pembrolizumab in patients with inoperable locally advanced or metastatic triple negative breast cancer
Session Info: Ongoing Clinical Trials: Immunotherapy (5 – 7 pm) Room: Hall 1
Shaveta Vinayak, MD, MS

Friday, December 7

Impact of molecular subtypes on long‐term outcomes in triple‐negative breast cancer (TNBC) patients treated with adjuvant AC chemotherapy on SWOG S9313
Poster Session 4: Prognostic & Predictive Factors: Prognostic Factors — clinical testing & validation (7:30 – 9 am) Room: Hall 1
Hannah M. Linden, MDPeggy Porter, MD

Novel human cell line xenograft models of ER‐positive metastatic invasive lobular breast carcinoma as pre‐clinical platforms for validating candidate genetic drivers
Spotlight Session: Lobular Breast Cancer (7 ‐9 am) Room: Stars at Night Ballroom 1 & 2
Nancy E. Davidson, MD

Investigating cortactin as a genetic driver of disease progression in invasive lobular carcinoma
Spotlight Session: Lobular Breast Cancer (7‐9 am) Room: Stars at Night Ballroom 1 & 2
Nancy E. Davidson, MD

Utilizing multiomic advanced diagnostics to identify CDK4/6 inhibitor response predictors and a posttreatment multiomic signature for patients with ER+/HER2‐ metastatic breast cancer (SIDEOUT‐3)
Ongoing Clinical Trials: Targeted ‐ CDK 4/6 (5‐6 pm) Room: Hall 1
Rachel L. Yung, MD

Saturday, December 8

Evaluation of multiple transcriptomic gene risk signatures in male breast cancer
Poster Session 6: Treatment: Male Breast Cancer (7:30 – 9 am) Room: Hall 1
Larissa Korde, MD, MPHPeggy Porter, MD